Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

Journal Articles

Human Mesenchymal Stem Cells Promote Resistance to Death Signals By Potentiating FGF Signaling in Mantle Cell Lymphoma

Lalit Sehgal, PhD, Rohit Mathur, PhD, Frank K Braun, PhD, Zuzana Berkova, PhD, Sattva Neelapu, MD, Felipe Samaniego, MD

Blood (2014) 124 (21): 5119.

https://doi.org/10.1182/blood.V124.21.5119.5119

Published: 2014

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

Journal Articles

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

Lalit Sehgal, Ph.D, Frank K Braun, PhD, Rohit Mathur, PhD, Sattva Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD, Felipe Samaniego, M.D., M.P.H

Blood (2013) 122 (21): 5051.

https://doi.org/10.1182/blood.V122.21.5051.5051

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Lijuan Wang, MD, PhD, Jianfei Qian, PhD, Yong Lu, PhD, Haiyan Li, MD, PhD, Sungyoul Hong, PhD, Hanying Bao, MD, PhD, Donghua He, MD, PhD, Zhiqiang Liu, PhD, Yuhuan Zheng, PhD, Jin He, PhD, Yongsheng Lan, PhD, Yi Li, MD, Sattva Neelapu, MD, Jing Yang, PhD, Michael Wang, MD, Cai Zhen, MD, PhD, Qing Yi, MD, PhD

Blood (2011) 118 (21): 2643.

https://doi.org/10.1182/blood.V118.21.2643.2643

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Liang Zhang, MD, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Michael Wang, MD, Qing Yi, MD, PhD

Blood (2010) 116 (21): 3929.

https://doi.org/10.1182/blood.V116.21.3929.3929

Published: 2010

Journal Articles

Targeting Multiple Myeloma with Human Ig Light Chain Specific Cytotoxic T Lymphocytes

Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2010) 116 (21): 3018.

https://doi.org/10.1182/blood.V116.21.3018.3018

Published: 2010

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.

Jianfei Qian, PhD, Sungyoul Hong, PhD, Liang Zhang, PhD, Yuhuan Zheng, PhD, Haiyan Li, PhD, Jing Yang, PhD, Sattva Neelapu, MD, Qing Yi, MD, PhD

Blood (2009) 114 (22): 465.

https://doi.org/10.1182/blood.V114.22.465.465

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD, Sattva Neelapu, MD, Michelle Fanale, MD, Maria Rodriguez, MD, Ana Ayala, RN, Barbara Pro, M.D., F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, Larry W. Kwak

Blood (2008) 112 (11): 3056.

https://doi.org/10.1182/blood.V112.11.3056.3056

Published: 2008

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Arnold S. Freedman, MD, Sattva Neelapu, MD, Craig R Nichols, MD, Michael Robertson, MD, Benjamin Djulbegovic, MD, PhD, Jane N. Winter, MD, Daniel Gold, PhD, John Bender, PharmD, Morgan Stewart, PhD, Richard G. Ghalie, MD, MBA, Paul A. Hamlin, Jr., MD

Blood (2008) 112 (11): 236.

https://doi.org/10.1182/blood.V112.11.236.236

Published: 2008

Journal Articles

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Saad Jamshed, MD, Daniel Fowler, MD, Sattva Neelapu, MD, Robert M. Dean, MD, Seth M Steinberg, PhD, Jeanne Odom, RN, Kelly Snow, RN, Ronald E Gress, MD, Michael R Bishop, MD

Blood (2008) 112 (11): 4328.

https://doi.org/10.1182/blood.V112.11.4328.4328

Published: 2008

Journal Articles

CD4 + Foxp3 + Regulatory T Cells Persist in High Numbers in Peripheral Blood after Induction of Clinical Remission with Standard Chemotherapy and Suppress Tumor-Specific Effector T Cells in Patients with Follicular Lymphoma

Myriam Foglietta, MD, David Delgado, Durgha Nattamai, Larry W Kwak, MD, PhD, Sattva Neelapu, MD

Blood (2008) 112 (11): 3778.

https://doi.org/10.1182/blood.V112.11.3778.3778

Published: 2008

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

NARROW

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Human Mesenchymal Stem Cells Promote Resistance to Death Signals By Potentiating FGF Signaling in Mantle Cell Lymphoma

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Targeting Multiple Myeloma with Human Ig Light Chain Specific Cytotoxic T Lymphocytes

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

CD4 + Foxp3 + Regulatory T Cells Persist in High Numbers in Peripheral Blood after Induction of Clinical Remission with Standard Chemotherapy and Suppress Tumor-Specific Effector T Cells in Patients with Follicular Lymphoma

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only